CM-101 in PSC Patients -The SPRING Study
Public ClinicalTrials.gov record NCT04595825. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects With Primary Sclerosing Cholangitis (The SPRING Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to assess the safety, tolerability and activity of the anti-human CCL24 monoclonal antibody CM-101 in adult subjects with Primary Sclerosing Cholangitis (PSC). At least 68 subjects at approximately 50 sites will be randomized to receive either CM-101 at doses of 10 mg/kg or 20 mg/kg or matching placebo.
Study identification
- NCT ID
- NCT04595825
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 77 participants
Conditions and interventions
Conditions
Interventions
- Anti-human CCL24 monoclonal antibody (CM-101) Biological
- Placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1, 2020 (Actual)
- Primary completion
- Jan 10, 2025 (Actual)
- Completion
- Jan 10, 2025 (Actual)
- Last update posted
- Jul 2, 2026
2020 – 2025
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scripps Clinic Torrey Pines - site P83 | La Jolla | California | 92037 | — |
| UC Davis Health System - Midtown Ambulatory Care Center - site P79 | Sacramento | California | 95816-5202 | — |
| Northwestern University - site P77 | Chicago | Illinois | 60611 | — |
| Massachusetts General Hospital - site P95 | Boston | Massachusetts | 02114 | — |
| Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC) - Liver Center - site P81 | Boston | Massachusetts | 02215 | — |
| Gastro One - GI Diagnostic and Therapeutic Endoscopy Center - 1310 Wolf Park - site P82 | Germantown | Tennessee | 38138-1741 | — |
| Methodist Dallas Medical Center - site P72 | Dallas | Texas | 75203 | — |
| Virginia Commonwealth - site P94 | Richmond | Virginia | 23284 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04595825, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 2, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04595825 live on ClinicalTrials.gov.